C WorldWide Group Holding A S decreased its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 47.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 71,670 shares of the specialty pharmaceutical company’s stock after selling 64,602 shares during the period. C WorldWide Group Holding A S owned 0.14% of Supernus Pharmaceuticals worth $3,089,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in SUPN. Creative Planning increased its stake in Supernus Pharmaceuticals by 251.8% in the first quarter. Creative Planning now owns 10,905 shares of the specialty pharmaceutical company’s stock valued at $341,000 after buying an additional 7,805 shares during the period. Juncture Wealth Strategies LLC increased its stake in Supernus Pharmaceuticals by 0.8% in the first quarter. Juncture Wealth Strategies LLC now owns 51,459 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after buying an additional 433 shares during the period. Louisiana State Employees Retirement System increased its stake in Supernus Pharmaceuticals by 2.5% in the first quarter. Louisiana State Employees Retirement System now owns 20,400 shares of the specialty pharmaceutical company’s stock valued at $639,000 after buying an additional 500 shares during the period. Legato Capital Management LLC increased its stake in Supernus Pharmaceuticals by 3,030.0% in the first quarter. Legato Capital Management LLC now owns 67,577 shares of the specialty pharmaceutical company’s stock valued at $2,159,000 after buying an additional 65,418 shares during the period. Finally, Capital Impact Advisors LLC acquired a new stake in Supernus Pharmaceuticals during the first quarter valued at $1,263,000. Institutional investors and hedge funds own 94.39% of the company’s stock.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ SUPN) opened at 41.40 on Friday. Supernus Pharmaceuticals, Inc. has a 12-month low of $17.25 and a 12-month high of $44.95. The company has a 50 day moving average price of $42.47 and a 200 day moving average price of $34.12. The company has a market capitalization of $2.10 billion, a P/E ratio of 20.89 and a beta of 1.31.

Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.24 by $0.08. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. The firm had revenue of $75.83 million for the quarter, compared to analyst estimates of $68.54 million. Equities analysts anticipate that Supernus Pharmaceuticals, Inc. will post $1.04 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/12/supernus-pharmaceuticals-inc-nasdaqsupn-shares-sold-by-c-worldwide-group-holding-a-s.html.

SUPN has been the subject of several research analyst reports. Jefferies Group LLC set a $35.00 target price on Supernus Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, May 10th. Cowen and Company lifted their target price on Supernus Pharmaceuticals from $31.00 to $34.00 and gave the stock an “outperform” rating in a research report on Thursday, May 11th. Cantor Fitzgerald lifted their target price on Supernus Pharmaceuticals from $25.00 to $27.00 and gave the stock an “overweight” rating in a research report on Thursday, May 11th. Piper Jaffray Companies upgraded Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $30.00 to $44.00 in a research report on Thursday, June 1st. Finally, BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 24th. Four equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $48.43.

In related news, VP Padmanabh P. Bhatt sold 2,556 shares of the stock in a transaction dated Friday, June 23rd. The stock was sold at an average price of $44.90, for a total transaction of $114,764.40. Following the transaction, the vice president now owns 24,944 shares of the company’s stock, valued at approximately $1,119,985.60. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Padmanabh P. Bhatt sold 5,500 shares of the stock in a transaction dated Thursday, May 25th. The stock was sold at an average price of $34.90, for a total value of $191,950.00. Following the transaction, the vice president now directly owns 43,887 shares in the company, valued at approximately $1,531,656.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 24,291 shares of company stock worth $962,766. 6.70% of the stock is owned by corporate insiders.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN).

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Stock Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.